FEMARA
LETROZOLE
Public price
1.021,00 MAD
Reimbursement base
713,00 MAD
Active substance
LETROZOLE
Reimbursable
What is this medicine?
A nonsteroidal competitive inhibitor of the aromatase enzyme system that inhibits the conversion of androgens to estrogens.
Verified summary
LETROZOLE, COMPRIME PELLICULE, 2.5 MG, 1 BOITE 30 COMPRIME PELLICULE
Common uses
Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer, extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy, and first and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
Class
aromatase inhibitor
Availability note
Reimbursable
Hospital price
742,00 MAD
Strength
2.5 MG
Form
COMPRIME PELLICULE
Presentation
1 BOITE 30 COMPRIME PELLICULE
Type
P
Therapeutic class
ANTINEOPLASIQUE CYTOTOXIQUE
This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.
Price history
Reference price recorded since 2017-12-18: 1.021,00 MAD
Available presentations and strengths
Medicines with the same active substance
LETROZOLE GT
2,5 MG · BOITE DE 60
1,11 MAD
LETROZOLE GT
2,5 MG · BOITE DE 10
211,00 MAD
LETROZOLE PHARMED
2,5 MG · BOITE DE 30
614,00 MAD
FEMISOL
2,5 MG · Boite de 30
630,00 MAD
LETROZOLE ZENITH
2,5 MG · BOITE DE 30
630,00 MAD
LETROZOLE ZENITH 2.5 MG
2.5 MG · Boîte de 30
630,00 MAD
LEZORA
2,5 MG · BOITE DE 28
632,00 MAD
ELOZOLE
2,5 MG · BOITE DE 30
712,00 MAD
LEFTARA
2,5 MG · BOITE DE 30
712,00 MAD
LEFTARA 2.5 MG
2.5 MG · Boite de 30
712,00 MAD
FEMOLET
2,5 MG · BOITE DE 30
713,00 MAD
LETROZOLE COOPER
2,5 MG · BOITE DE 30
713,00 MAD